biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Stagliano's Neuron23 Raises Another $100 million

<< Previous

Bullboard Posts

Next >>

Comment by Aarcoron Mar 30, 2022 7:07pm

81 Views

Post# 34560943

RE:RE:RE:Stagliano's Neuron23 Raises Another $100 million

Thanks for posting JD.

Other management teams in the same space can garner large amounts of cash to fund their objectives, while Rathjen struggles to get 1% of that. Neuron23 or whatever its called will plot its own course and control its own destiny.

And of course, another reminder, that the longer BTI produces no publishable advancements, the larger the threat to the company's one and only asset.

Please spare me the usual drivel that there is so much happening in the background but investors and shareholders are just not smart enough to figure it all out.

25 cents.

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program